JP2024514203A5 - - Google Patents

Info

Publication number
JP2024514203A5
JP2024514203A5 JP2023563211A JP2023563211A JP2024514203A5 JP 2024514203 A5 JP2024514203 A5 JP 2024514203A5 JP 2023563211 A JP2023563211 A JP 2023563211A JP 2023563211 A JP2023563211 A JP 2023563211A JP 2024514203 A5 JP2024514203 A5 JP 2024514203A5
Authority
JP
Japan
Prior art keywords
icd
zeta signaling
cells
dap12
signaling domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023563211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514203A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/024842 external-priority patent/WO2022221548A1/en
Publication of JP2024514203A publication Critical patent/JP2024514203A/ja
Publication of JP2024514203A5 publication Critical patent/JP2024514203A5/ja
Pending legal-status Critical Current

Links

JP2023563211A 2021-04-14 2022-04-14 Cd5陽性がんを標的とするキメラ抗原受容体 Pending JP2024514203A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163174990P 2021-04-14 2021-04-14
US63/174,990 2021-04-14
PCT/US2022/024842 WO2022221548A1 (en) 2021-04-14 2022-04-14 Chimeric antigen receptors to target cd5-positive cancers

Publications (2)

Publication Number Publication Date
JP2024514203A JP2024514203A (ja) 2024-03-28
JP2024514203A5 true JP2024514203A5 (cg-RX-API-DMAC7.html) 2025-02-21

Family

ID=83640731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563211A Pending JP2024514203A (ja) 2021-04-14 2022-04-14 Cd5陽性がんを標的とするキメラ抗原受容体

Country Status (11)

Country Link
US (1) US20240189357A1 (cg-RX-API-DMAC7.html)
EP (1) EP4322992A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024514203A (cg-RX-API-DMAC7.html)
KR (1) KR20240007911A (cg-RX-API-DMAC7.html)
CN (1) CN117480187A (cg-RX-API-DMAC7.html)
AU (1) AU2022259658A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021133A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216557A1 (cg-RX-API-DMAC7.html)
IL (1) IL307408A (cg-RX-API-DMAC7.html)
MX (1) MX2023012180A (cg-RX-API-DMAC7.html)
WO (1) WO2022221548A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4332118A1 (en) * 2021-04-29 2024-03-06 Korea Research Institute of Bioscience and Biotechnology Novel anti-cd5 chimeric antigen receptor and immune cell expressing same
CA3233096A1 (en) * 2021-10-20 2023-04-17 Board Of Regents, The University Of Texas System Engineering nk cells with a car construct with optimal signaling
EP4419541A4 (en) * 2021-10-21 2025-12-17 Univ Texas METHOD FOR PRODUCING THERAPEUTIC IMMUNE CELLS WITH IMPROVED METABOLIC FITNESS AND COMPOSITIONS THEREOFUL
AU2024280012A1 (en) * 2023-06-02 2025-12-11 Board Of Regents, The University Of Texas System Selection of cryopreserved cord blood units for the manufacture of natural killer cells with enhanced potency
WO2025038813A1 (en) * 2023-08-16 2025-02-20 Beam Therapeutics Inc. Cd5-binding polypeptides, compositions comprising the same, and methods for use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2977106A1 (en) * 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
MA41962A (fr) * 2015-04-23 2018-02-28 Baylor College Medicine Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
AU2016274989A1 (en) * 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
US20180371052A1 (en) * 2015-12-22 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors and enhancement of anti-tumor activity
CN110475857B (zh) * 2017-01-05 2023-07-18 韩国生命工学研究院 表达抗-可替宁嵌合抗原受体的天然杀伤细胞
US20230159618A1 (en) * 2017-07-25 2023-05-25 Board Of Regents, The University Of Texas System Enhanced chimeric antigen receptors and use thereof
TW201908335A (zh) * 2017-07-25 2019-03-01 美國德州系統大學評議委員會 增強之嵌合抗原受體及其用途

Similar Documents

Publication Publication Date Title
Ghasemi et al. Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy
US20220370501A1 (en) Methods for enhancing efficacy of therapeutic immune cells
JP7258364B2 (ja) がんおよび関連悪性腫瘍の治療のためのγδT細胞を活性化、修飾、および増殖させる方法
JP2024138280A5 (cg-RX-API-DMAC7.html)
Bontkes et al. Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells
JP2024521185A5 (cg-RX-API-DMAC7.html)
JP2018500944A5 (cg-RX-API-DMAC7.html)
Murad et al. Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy
JP2023539361A5 (cg-RX-API-DMAC7.html)
JP2022550899A5 (cg-RX-API-DMAC7.html)
JP2018522567A5 (cg-RX-API-DMAC7.html)
EP2614151B1 (en) Interleukin 15 as selectable marker for gene transfer in lymphocytes
JP7572700B2 (ja) 改変ヒト初代血液樹状細胞株を生成するための方法
JP2017512484A5 (cg-RX-API-DMAC7.html)
JP2024525609A5 (cg-RX-API-DMAC7.html)
JP2021525534A5 (cg-RX-API-DMAC7.html)
CN107847585A (zh) 用于得到体内存留性和治疗活性的nkt细胞亚群以及其繁殖
Schaft et al. T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNγ production
JP2024527879A5 (cg-RX-API-DMAC7.html)
Yu et al. Revolution of CAR engineering for next-generation immunotherapy in solid tumors
Lv et al. γδT cells, a key subset of T cell for cancer immunotherapy
JP2022513164A5 (cg-RX-API-DMAC7.html)
Dörrie et al. Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes
JP2022513099A5 (cg-RX-API-DMAC7.html)
EP4423121A1 (en) Methods for culturing cells expressing c-jun